Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 1/20 | 0.48 |
| ▸ | JUN | P05412 | 3/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.47 |
| ▸ | DHODH | Q02127 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
| ▸ | CDK4 | P11802 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 3/20 | 0.45 |
| ▸ | TDO2 | P48775 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1287081 | 0.88 | BCL2 (0.49) | BCL2PTGDR2MAPTALDH1A1KMT2A | |
| SCHEMBL1287142 | 0.86 | RAB9A (0.50) | BCL2PTGDR2DHODHKDM4EMAPT | |
| SCHEMBL1287135 | 0.84 | IDO1 (0.59) | BCL2PTGDR2KDM4EMAPTALDH1A1 | |
| SCHEMBL1287124 | 0.83 | MEN1 (0.51) | BCL2KDM4EMAPTALDH1A1KMT2A | |
| SCHEMBL1287085 | 0.83 | DHODH (0.47) | BCL2PTGDR2DHODHMAPTIDO1 | |
| SCHEMBL1287131 | 0.82 | MAPT (0.47) | BCL2KDM4EMAPTALDH1A1KMT2A | |
| SCHEMBL10220599 | 0.76 | IDO1 (0.51) | BCL2JUNKDM4EMAPTALDH1A1 | |
| SCHEMBL7757594 | 0.74 | MAPT (0.45) | JUNPTGDR2KDM4EMAPTALDH1A1 | |
| SCHEMBL7818266 | 0.74 | IDO1 (0.55) | KDM4EMAPTALDH1A1KMT2APOLB | |
| SCHEMBL4395567 | 0.69 | ADORA2B (0.71) | PTGDR2DHODHKDM4EMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040713-B2 | Methods of managing blood sugar levels and compositions related thereto | EMORY UNIVERSITY (US) | 2015-05-26 | — | — | US | claimed |
| US-20130158082-A1 | METHODS OF MANAGING BLOOD SUGAR LEVELS AND COMPOSITIONS RELATED THERETO | EMORY UNIVERSITY (US) | 2013-06-20 | — | — | US | claimed |
| WO-2012047628-A2 | METHODS OF MANAGING BLOOD SUGAR LEVELS AND COMPOSITIONS RELATED THERETO | EMORY UNIVERSITY (US) | 2012-04-12 | — | — | WO | claimed |
| US-20230044407-A1 | TARGETING MB2 OF THE MYC ONCOGENE AND ITS INTERACTION WITH TRRAP IN CANCER | THE TRUSTEES OF DARTMOUTH COLLEGE | 2023-02-09 | — | — | US | disclosed |
| US-20230044407-A1 | TARGETING MB2 OF THE MYC ONCOGENE AND ITS INTERACTION WITH TRRAP IN CANCER | THE TRUSTEES OF DARTMOUTH COLLEGE | 2023-02-09 | — | — | US | disclosed |
| WO-2021113347-A1 | TARGETING MB2 OF THE MYC ONCOGENE AND ITS INTERACTION WITH TRRAP IN CANCER | THE TRUSTEES OF DARTMOUTH COLLEGE (US) | 2021-06-10 | — | — | WO | disclosed |
| US-9040713-B2 | Methods of managing blood sugar levels and compositions related thereto | EMORY UNIVERSITY (US) | 2015-05-26 | — | — | US | disclosed |
| US-20130158082-A1 | METHODS OF MANAGING BLOOD SUGAR LEVELS AND COMPOSITIONS RELATED THERETO | EMORY UNIVERSITY (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2012047628-A2 | METHODS OF MANAGING BLOOD SUGAR LEVELS AND COMPOSITIONS RELATED THERETO | EMORY UNIVERSITY (US) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230044407-A1 | TARGETING MB2 OF THE MYC ONCOGENE AND ITS INTERACTION WITH TRRAP IN CANCER | MYCBP, MYC, TERF2IP | BCL2 854/4885JUN 321/4885PTGDR2 2562/4885 |
| US-20130158082-A1 | METHODS OF MANAGING BLOOD SUGAR LEVELS AND COMPOSITIONS RELATED THERETO | SLC5A1, SLC2A1, SLC5A2 | BCL2 2214/4885JUN 2109/4885PTGDR2 4406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.